Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. This marks a significant advancement in the therapeutic landscape for cervical cancer, highlighting the potential of antibody-drug conjugates (ADCs) in oncology.

From Sino Biological Inc. 10 May 2024

Enhancing the ability of natural killer cells to combat hematologic malignancies

A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability of human natural killer (NK) cells to lyse hematologic malignancies (HMs).

9 May 2024

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesting potential for new COVID-19 treatments.

9 May 2024

Researchers enhance CAR-T cells to target solid tumors

Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors-;an advance that could transform cancer treatment.

8 May 2024

Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorization Application for TREMFYA® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.

6 May 2024

New monoclonal antibody vaccine slashes malaria risk in children

A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.

30 Apr 2024

Experimental monoclonal antibody prevents and reverses clinical type 1 diabetes in mice

Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals' lifespan.

29 Apr 2024

Single dose of malaria monoclonal antibody 77% effective in children, trial in Mali shows

One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country's six-month malaria season, according to the results of a mid-stage clinical trial.

26 Apr 2024

Analysis finds significant variations in national COVID-19 treatment recommendations

National clinical guidelines for the treatment of COVID-19 vary significantly around the world, with under-resourced countries the most likely to diverge from gold standard (World Health Organization; WHO) treatment recommendations, finds a comparative analysis published in the open access journal BMJ Global Health.

23 Apr 2024

Study identifies potential strategy to diminish the devastating impacts of traumatic brain injuries

For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.

22 Apr 2024

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients with rapidly progressing forms, using phase II clinical trial data.

19 Apr 2024

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

New research to be presented at next week's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients.

18 Apr 2024

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

10 Apr 2024

UVA researchers discover Y chromosome gene linked to heart failure in men

University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that contributes to the greater incidence of heart failure in men.

1 Apr 2024

Clinical trial to test the feasibility of using at-home cancer immunotherapy

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

28 Mar 2024

ArgusEye introduces AugaOne to accelerate downstream bioprocess development

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the introduction of the AugaOne™ sensor system.

21 Mar 2024

Sino Biological announces services partnership with Rapid Novor

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).

From Sino Biological Inc. 21 Mar 2024

New fluid biomarker may one day detect ALS and FTD before symptoms appear

Two progressively degenerative diseases, amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease) and frontotemporal dementia (FTD, recently in the news with the diagnoses of actor Bruce Willis and talk show host Wendy Williams), are linked by more than the fact that they both damage nerve cells critical to normal functioning -; the former affecting nerves in the brain and spinal cord leading to loss of movement, the latter eroding the brain regions controlling personality, behavior and language.

18 Mar 2024

NIH study uncovers vulnerable sites on Epstein-Barr virus protein

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

12 Mar 2024

Study reveals safety of MS drugs during breastfeeding in child's early years of life

Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, according to a preliminary study released today, March 4, 2024.

4 Mar 2024